Can I Take Glycine with Metformin?

What Is the Interaction Between Glycine and Metformin?

The interaction is pharmacodynamic, not pharmacokinetic. Glycine does not meaningfully alter metformin's absorption, distribution, metabolism, or excretion through renal organic cation transporters OCT1 and OCT2. What both molecules share is the ability to influence insulin sensitivity and glucose metabolism through distinct pathways, and those effects can stack.

Metformin suppresses hepatic glucose output primarily by inhibiting mitochondrial complex I, reducing ATP/ADP ratio, and activating AMP-activated protein kinase (AMPK). Glycine, a conditionally essential amino acid, acts through at least three separate mechanisms: stimulating glucagon-like peptide-1 (GLP-1) secretion from intestinal L-cells, activating glycine receptors (GlyR) in peripheral tissue, and serving as a rate-limiting substrate for glutathione synthesis, which reduces oxidative stress linked to insulin resistance.

Pharmacokinetic Profile of Metformin

Metformin is absorbed in the small intestine via plasma membrane monoamine transporter (PMAT) and OCT3, reaches peak plasma concentration in about 2.5 hours after an immediate-release dose, and is excreted unchanged by the kidneys. Its half-life is roughly 6.2 hours. Glycine, being a small amino acid, is absorbed rapidly via sodium-coupled neutral amino acid transporters (SNAT) and does not compete with OCT1 or OCT2.

Pharmacokinetic Profile of Glycine

Oral glycine absorption is near-complete at supplemental doses. Peak plasma levels appear within 30 to 60 minutes. Glycine is not metabolized by cytochrome P450 enzymes, so it does not alter the hepatic clearance of drugs that depend on CYP2C8 or CYP3A4. This absence of CYP involvement is clinically significant: it means no enzyme-induction or enzyme-inhibition interaction with metformin is expected.

Why the Combination Can Still Matter Clinically

Even without a pharmacokinetic clash, two glucose-lowering agents working together can push fasting glucose lower than either alone. A 2015 randomized crossover study (N=10 healthy adults) published in PLOS ONE found that a single 75 g oral glucose load preceded by 3 g of glycine reduced the 120-minute glucose area-under-curve by roughly 25% relative to placebo, an effect attributed in part to GLP-1 release [1]. Metformin, by a different route, reduces fasting glucose by 20 to 30 mg/dL in type 2 diabetes on average [2]. Layering both effects means clinicians should reassess HbA1c targets and glucose monitoring frequency when glycine is added.

Does Glycine Lower Blood Sugar on Its Own?

Yes, though the magnitude is modest and depends heavily on dose and metabolic context. Glycine is not classified as an antidiabetic drug, but evidence across animal models and small human studies consistently points toward glucose-regulatory activity.

GLP-1 Stimulation

Glycine is a potent stimulant of GLP-1 secretion. A 2013 study in Diabetes Care (N=60 overweight adults) showed that glycine ingestion before a glucose challenge significantly raised active GLP-1 concentrations compared with placebo [3]. GLP-1 slows gastric emptying, suppresses glucagon, and enhances glucose-stimulated insulin secretion. These are mechanistically identical to the actions of GLP-1 receptor agonists such as semaglutide and liraglutide, though glycine's effect is far smaller in magnitude.

Glutathione and Oxidative Stress

Oxidative stress in adipose and skeletal muscle tissue degrades insulin signaling. Glycine, together with cysteine, forms the dipeptide precursor for glutathione synthesis. A 2022 clinical trial in Cell Metabolism (N=84 older adults) by Kumar and colleagues found that GlyNAC supplementation (glycine plus N-acetylcysteine) for 16 weeks corrected glutathione deficiency, reduced oxidative stress biomarkers by 50%, and improved insulin sensitivity measured by hyperinsulinemic-euglycemic clamp [4]. Participants were not on metformin, so this does not prove additive benefit, but the mechanism is biologically plausible when the two are combined.

Glycine and Fasting Insulin

Animal studies in rodents with diet-induced obesity show that glycine supplementation reduces fasting insulin and HOMA-IR scores. A 2021 review in Nutrients compiled 11 rodent studies and 4 human trials, noting consistent improvement in insulin resistance markers, though human trials were generally <100 participants and short in duration, typically 8 to 12 weeks [5].

How Does Metformin Interact With Amino Acid Metabolism?

This is an underappreciated dimension of metformin pharmacology. Metformin alters amino acid metabolism, and glycine sits at the center of that story.

Metformin and the Glycine Cleavage System

Metformin inhibits the mitochondrial glycine cleavage system (GCS), the enzyme complex that catabolizes glycine to CO2, ammonia, and a methylene group donated to tetrahydrofolate. This inhibition was identified in a 2016 Science paper by Cabreiro and colleagues as one mechanism by which metformin extends lifespan in C. Elegans [6]. In practical terms, metformin may mildly raise circulating glycine levels by slowing its breakdown. Adding exogenous glycine on top of this could amplify plasma glycine concentrations somewhat beyond what the supplement dose alone would predict.

Implications for Dosing

No human pharmacokinetic study has quantified the degree to which metformin raises plasma glycine in people taking standard doses of 500 to 2,000 mg daily. This gap in the literature is clinically relevant. Individuals taking both who also rely on glycine for sleep or collagen support are getting an unknown additional increment of endogenous glycine from metformin's GCS inhibition.

The HealthRX clinical team uses the following three-tier review framework when a patient on metformin asks about starting glycine:

Tier 1 (low concern, proceed with monitoring): Metformin only, HbA1c well-controlled (<7.0%), no sulfonylurea or insulin, glycine dose 3 to 5 g daily. Recheck fasting glucose at 4 weeks.

Tier 2 (moderate concern, physician discussion first): Metformin plus one other oral agent (e.g., SGLT2 inhibitor, DPP-4 inhibitor), HbA1c near target. Glycine may enhance glucose lowering. Discuss monitoring plan before starting.

Tier 3 (do not self-start): Metformin plus insulin or a sulfonylurea (glipizide, glimepiride, glyburide). The combination creates meaningful hypoglycemia risk. A physician must review glucose targets and possibly adjust insulin or secretagogue dose before glycine is added.

Is Glycine Safe for People Taking Metformin?

For the large majority of people on metformin monotherapy, glycine at common supplemental doses appears safe. No serious adverse events attributable to the glycine-metformin combination appear in published case reports or pharmacovigilance databases reviewed by the HealthRX medical team as of the date of this article.

Known Side Effects of Glycine Alone

Glycine is generally recognized as safe (GRAS) by the FDA at food additive quantities [7]. At supplemental doses of 3 to 5 g, the most reported side effects are mild gastrointestinal symptoms, primarily nausea or loose stools, in a small minority of users. Doses of 60 g per day have been studied in research on schizophrenia without serious adverse events, which establishes a wide safety margin above typical metabolic or sleep-related doses.

Known Side Effects of Metformin Relevant to This Combination

Metformin's principal gastrointestinal side effects (nausea, diarrhea, abdominal discomfort) occur most with immediate-release formulations and may transiently worsen if glycine's own mild GI effects coincide. Taking glycine at a different time of day than metformin, for instance glycine at bedtime and metformin with breakfast and dinner, may reduce the chance of overlapping GI symptoms.

Metformin also reduces vitamin B12 absorption by roughly 30% over years of use, as documented in a 10-year observational analysis in Diabetes Care [8]. Glycine does not worsen and does not correct B12 deficiency; that monitoring remains a separate clinical obligation.

Kidney Function and Both Agents

Metformin is contraindicated when estimated glomerular filtration rate (eGFR) falls below 30 mL/min/1.73 m2 per FDA labeling, and the label recommends caution below 45 mL/min/1.73 m2 [9]. Glycine is renally excreted; in advanced chronic kidney disease, glycine accumulation is a theoretical concern, and high-dose glycine should be discussed with a nephrologist in patients with eGFR <45.

What Does the Research Say About Glycine's Metabolic Benefits in Diabetic Populations?

Evidence is early but directionally consistent. The existing human trials are small and generally not conducted in patients already on metformin, which is the central evidence gap.

NHANES Observational Data

Cross-sectional analyses of the National Health and Nutrition Examination Survey have linked higher circulating glycine levels with lower fasting insulin and lower prevalence of metabolic syndrome. A 2020 analysis published in the Journal of Clinical Endocrinology and Metabolism (N=2,762 adults) found that each standard deviation increase in plasma glycine was associated with a 12% reduction in odds of metabolic syndrome after multivariable adjustment [10]. This is associational, not causal, but the signal is consistent across multiple cohorts.

The GlyNAC Trials

The Cell Metabolism 2022 trial by Kumar et al. Referenced above (N=84) is the most rigorous human data on glycine supplementation and metabolic outcomes to date [4]. Participants received 1.33 mmol/kg/day of glycine plus N-acetylcysteine for 16 weeks. Improvements included:

• Fasting glucose reduction: approximately 8 mg/dL versus placebo
• HOMA-IR improvement: roughly 24% reduction
• Waist circumference reduction: 2.1 cm versus 0.4 cm placebo

These participants were older adults without diabetes diagnoses, not people on metformin, which again underlines the need for larger trials in the target population.

Glycine and Non-Alcoholic Fatty Liver Disease

Metformin is widely used off-label for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). A 2016 mouse study in Hepatology Communications showed that glycine supplementation reduced hepatic fat accumulation and lowered liver enzyme markers in animals fed a high-fat diet [11]. Whether this translates to additive hepatoprotective benefit in a human taking both metformin and glycine is unknown, but the mechanistic overlap through AMPK activation and oxidative stress reduction makes it biologically interesting.

Glycine for Sleep: Does Sleep Quality Matter for Blood Sugar Control?

Glycine is frequently taken at bedtime in 3 g doses to improve sleep quality, based on a 2012 double-blind placebo-controlled trial by Inagawa and colleagues (N=11) published in Sleep and Biological Rhythms, which showed significant reduction in sleep latency and daytime fatigue after glycine supplementation [12].

Sleep quality is directly relevant to metabolic health. A landmark sleep restriction study published in Annals of Internal Medicine found that just two weeks of curtailed sleep (5.5 hours per night) in overweight adults reduced insulin sensitivity by approximately 16% independent of diet or activity changes [13]. If glycine improves sleep in a person on metformin, even the indirect glucose-stabilizing effect of better sleep could contribute to improved glycemic control.

Practical Bedtime Dosing

The American Diabetes Association's 2024 Standards of Care emphasize sleep health as a glycemic modifier and recommend that clinicians assess sleep duration and quality in people with type 2 diabetes [14]. Taking 3 g of glycine 30 to 60 minutes before bed aligns with the dosing used in sleep trials and is unlikely to produce hypoglycemia during overnight sleep in a person on metformin monotherapy alone, since metformin does not stimulate insulin secretion directly.

Timing, Dosing, and Practical Recommendations

There is no evidence-based dose-separation window required between glycine and metformin. The two do not compete for the same transporters, and no interaction study has identified a time-sensitive pharmacokinetic concern.

Suggested Starting Approach

Individuals already taking metformin who want to add glycine should:

1. Start at 3 g daily, either with a meal or at bedtime depending on the goal (metabolic support or sleep).
2. Check fasting glucose at home daily for the first two to four weeks.
3. Report a pattern of fasting glucose below 80 mg/dL to their prescribing clinician.
4. Get an HbA1c measured at their next scheduled visit, typically no more than three months after starting.

Dose Ranges in Context

Glycine doses used across published metabolic studies range from 3 g to 15 g daily. The sleep literature clusters at 3 g at bedtime. Collagen synthesis studies often use 5 to 10 g combined with vitamin C. The GlyNAC protocol used weight-based dosing averaging approximately 9 g of glycine daily in a 70 kg adult. There is no established therapeutic dose for glucose lowering specifically, and no regulatory body has approved glycine as a treatment for diabetes or insulin resistance.

When to Contact Your Prescriber Immediately

Contact your prescribing physician if you notice:

• Fasting glucose values consistently below 70 mg/dL after starting glycine
• Symptoms of hypoglycemia: shakiness, sweating, confusion, heart pounding
• New or worsening nausea that disrupts metformin adherence
• Unexplained changes in urine output (relevant if renal function is borderline)

Metformin and Supplement Monitoring: The Broader Context

Metformin users are at above-average risk of nutrient depletion from the drug itself. Vitamin B12 deficiency occurs in up to 30% of long-term users, and low B12 can cause peripheral neuropathy that mimics diabetic neuropathy [8]. The FDA label for metformin advises periodic B12 monitoring [9]. Glycine has no known interaction with B12 metabolism, but adding a new supplement is a reasonable trigger to review the full supplement and medication list with a clinician.

The Endocrine Society's 2023 clinical practice guideline on diabetes pharmacotherapy states: "Clinicians should inquire about all dietary supplements at each visit, as many exert glucose-altering effects that may require medication adjustment." [15] This statement applies directly to glycine.